BioSpace News Archive

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, announced that it has commenced an underwritten public offering of up to $400,000,000 of shares of its common stock.

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Jennifer Chien has been appointed as Executive Vice President, Head of North America, effective November 9, 2020. As EVP North America, Ms. Chien will co-lead global integrated commercial strategies in close collaboration with Yann Mazabraud, who

Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the presentation of preclinical data highlighting the potential of its modular biologics pipeline for the treatment of autoimmune diseases at the Federation of Clinical Immunology Societies (FOCIS) 2020 virtual annual meeting.

R1 RCM Inc. (NASDAQ:RCM), a leader in technology-enabled revenue cycle management (RCM) services to healthcare providers, and LifePoint Health, a national network of hospitals, post-acute services, outpatient centers and providers in more than 80 locations, have entered into a new revenue cycle management agreement that will make R1 the exclusive revenue cycle management partner for more than one-third of LifePoint hospitals

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech,” or “the Company”) is pleased to announce that the launch of a larger consumer product test to further prove the efficacy of the Company’s shampoo on dermatitis and dandruff began on October 14, 2020.

T wo pilot studies initiated to explore clinical applications for this convenient, one-time injectable treatment - P osition s Scout Bio as the first company to advance novel GLP-1 constructs for gene therapy in companion animals -

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2020, on Thursday, November 5, 2020, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Thursday, November 5 th @ 8:30am

-Reported positive top-line results from the Company’s ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110™, targeting CD19+ B-cell malignancies- - Received Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) for CTX001™ for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)- -Received Orphan Drug Designation (ODD) for Phase 1 clinical trial of CTX120™, targeting B-cell maturation antigen (BCMA)-

BetterLife Pharma, an emerging biotechnology company preparing human clinical trials of AP-003, its interferon alpha 2b inhalation therapy for the treatment of COVID-19, provided the following update regarding how it expects to overcome potential challenges of recruiting patients for human trials.

Pathnostics, a diagnostic solutions company, today announced that it has launched a multiplex polymerise chain reaction (PCR) test that simultaneously detects multiple respiratory infections, including COVID-19, influenzas A/B and respiratory syncytial virus (RSV).